Li Wei, Lv Xuan, Ma Yijun, Cai Yong, Zhu Suijun
Department of Neurosurgery, First People's Hospital of Linping District, Hangzhou, China.
Department of Neurosurgery, Linping Campus, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Front Neurol. 2023 Mar 10;14:1125674. doi: 10.3389/fneur.2023.1125674. eCollection 2023.
Caspase activation and recruitment domain-containing protein 4 (NLRC4) is implicated in neuroinflammation. The aim of the study was to discern the potential ability of serum NLRC4 in assessment of prognosis after intracerebral hemorrhage (ICH).
In this prospective, observational study, serum NLRC4 levels were quantified in 148 acute supratentorial ICH patients and 148 controls. Severity was evaluated using the National Institutes of Health Stroke Scale (NIHSS) and hematoma volume, and poststroke 6-month functional outcome was estimated according to the modified Rankin Scale (mRS). Early neurologic deterioration (END) and 6-month poor outcome (mRS 3-6) were deemed as the two prognostic parameters. Multivariate models were established for investigating associations, and receiver operating characteristic (ROC) curves were configured to indicate predictive capability.
Patients had substantially higher serum NLRC4 levels than controls (median, 363.2 pg/ml vs. 74.7 pg/ml). Serum NLRC4 levels had independent correlation with NIHSS scores [β, 0.308; 95% confidence interval (CI), 0.088-0.520], hematoma volume (β, 0.527; 95% CI, 0.385-0.675), serum C-reactive protein levels (β, 0.288; 95% CI, 0.109-0.341) and 6-month mRS scores (β, 0.239; 95% CI, 0.100-0.474). Serum NLRC4 levels above 363.2 pg/ml were independently predictive of END (odds ratio, 3.148; 95% CI, 1.278-7.752) and 6-month poor outcome (odds ratio, 2.468; 95% CI, 1.036-5.878). Serum NLRC4 levels significantly distinguished END risk [area under ROC curve (AUC), 0.765; 95% CI, 0.685-0.846] and 6-month poor outcome (AUC, 0.795; 95% CI, 0.721-0.870). In terms of predictive ability for 6-month poor outcome, serum NLRC4 levels combined with NIHSS scores and hematoma volume was superior to NIHSS scores combined with hematoma volume, NIHSS scores and hematoma volume (AUC, 0.913 vs. 0.870, 0.864 and 0.835; all < 0.05). Nomograms were built to reflect prognosis and END risk of combination models, where serum NLRC4, NIHSS scores and hematoma volume were enforced. Calibration curves confirmed stability of combination models.
Markedly raised erum NLRC4 levels following ICH, in close relation to illness severity, are independently associated with poor prognosis. Such results are indicative of the notion that determination of serum NLRC4 may aid in severity assessment and prediction of functional outcome of ICH patients.
含半胱天冬酶激活和募集结构域蛋白4(NLRC4)与神经炎症有关。本研究旨在探讨血清NLRC4在评估脑出血(ICH)后预后方面的潜在能力。
在这项前瞻性观察研究中,对148例急性幕上ICH患者和148例对照者的血清NLRC4水平进行了定量分析。使用美国国立卫生研究院卒中量表(NIHSS)和血肿体积评估病情严重程度,并根据改良Rankin量表(mRS)评估卒中后6个月的功能结局。早期神经功能恶化(END)和6个月时预后不良(mRS 3 - 6)被视为两个预后参数。建立多变量模型以研究相关性,并绘制受试者工作特征(ROC)曲线以显示预测能力。
患者的血清NLRC4水平显著高于对照组(中位数,363.2 pg/ml对74.7 pg/ml)。血清NLRC4水平与NIHSS评分[β,0.308;95%置信区间(CI),0.088 - 0.520]、血肿体积(β,0.527;95% CI,0.385 - 0.675)、血清C反应蛋白水平(β,0.288;95% CI,0.109 - 0.341)和6个月mRS评分(β,0.239;95% CI,0.100 - 0.474)独立相关。血清NLRC4水平高于363.2 pg/ml可独立预测END(比值比,3.148;95% CI,1.278 - 7.752)和6个月时预后不良(比值比,2.468;95% CI,1.036 - 5.878)。血清NLRC4水平能显著区分END风险[ROC曲线下面积(AUC),0.765;95% CI,0.685 - 0.846]和6个月时预后不良(AUC,0.795;95% CI,0.721 - 0.870)。在预测6个月时预后不良的能力方面,血清NLRC4水平联合NIHSS评分和血肿体积优于NIHSS评分联合血肿体积、NIHSS评分和血肿体积(AUC,0.913对0.870、0.864和0.835;均P < 0.05)。构建列线图以反映联合模型的预后和END风险,其中纳入了血清NLRC4、NIHSS评分和血肿体积。校准曲线证实了联合模型的稳定性。
ICH后血清NLRC4水平显著升高,与疾病严重程度密切相关,独立于预后不良相关。这些结果表明,测定血清NLRC4可能有助于评估ICH患者的病情严重程度和预测功能结局。